Women, Pregnancy, and Substance Use

From Telescoping to the Fourth Trimester — A Comprehensive Clinical Guide

Executive Summary

Women represent the fastest-growing demographic for substance use disorders, yet treatment models remain largely male-centric. The "gender gap" is closing: women's AUD rates are rising 84% faster than men's, and drug overdose is now a leading cause of pregnancy-associated death. The "Fourth Trimester"—7-12 months postpartum—represents the highest risk period for maternal overdose.

🔑 Key Points

  • MOUD (methadone/buprenorphine) is first-line for perinatal OUD—NOT detox
  • CYP3A4 induction in pregnancy requires dose increases in 2nd/3rd trimester
  • NOWS: Eat-Sleep-Console (ESC) protocol reduces pharmacologic treatment by ~50%
  • No FDA-approved medications for stimulant use disorder—Contingency Management is gold standard
  • Overdose risk peaks 7-12 months postpartum ("Fourth Trimester cliff")
  • CAPTA requires notification, not necessarily CPS abuse report

The Telescoping Effect

Women exhibit accelerated progression from initiation to dependence and medical consequences despite lower absolute consumption. This "telescoping" is driven by:

⚠️ Clinical Implication

Women get "sicker, quicker" despite lower absolute consumption. Screen women with lower thresholds; don't dismiss because "she doesn't drink that much."

Perinatal Opioid Use Disorder

MOUD vs. Detox in Pregnancy

🚨 Standard of Care

MOUD (methadone or buprenorphine) is first-line. Medically supervised withdrawal has relapse rates of 59–90% and risks fetal hypoxia, loss of tolerance → overdose, and HIV/HCV risk.

Withdrawal is more dangerous to the fetus than stable opioid maintenance.

Methadone vs. Buprenorphine

Feature Methadone Buprenorphine
Structure Full agonist Partial agonist
Setting OTP (daily visits) OBOT (prescription)
NOWS Severity More severe Less severe (MOTHER study)
Induction No withdrawal required Requires mild withdrawal (PWD risk)

Pregnancy Pharmacokinetics: The "4 PM Wall"

Progesterone induces CYP3A4 (2-3× increase) and plasma volume expands 30-50% in pregnancy. This shortens methadone/buprenorphine half-life significantly.

💡 Clinical Management

  • Split dosing (BID/TID) or increase total daily dose by 25-50% in 2nd/3rd trimester
  • "The 4 PM Wall": Afternoon/evening withdrawal despite stable AM dose
  • Maternal withdrawal stresses the fetus—stable mom = stable baby

Neonatal Opioid Withdrawal Syndrome (NOWS)

Pathophysiology

Noradrenergic hyperactivity upon cessation of maternal opioids. Previously called "NAS"—now NOWS to reflect that it's a withdrawal syndrome, not an addiction.

Assessment Shift: Finnegan → Eat-Sleep-Console (ESC)

Approach Finnegan ESC (Evidence-Based)
Focus Counting symptoms Functional assessment
Key Questions "How many symptoms?" "Can baby eat, sleep, be consoled?"
Treatment Impact Higher pharmacologic treatment rates ~50% reduction in morphine need

Non-Pharmacologic First Line

Stimulant Use in Pregnancy

Epidemiology

Methamphetamine and cocaine use rising in rural and Black/Indigenous populations. No FDA-approved medications for stimulant use disorder.

Pregnancy Risks

Treatment: Contingency Management (CM)

✅ Gold Standard

CM (incentives/vouchers for negative UDS) has the strongest evidence base for stimulant use disorder. No pharmacologic substitute exists.

Differential: Stimulant Intoxication vs. Postpartum Psychosis

Acute stimulant intoxication can mimic postpartum psychosis. Key distinction:

Safety first: Assess infant safety and maternal capacity to care for infant.

The Fourth Trimester: The Relapse Danger Zone

🚨 Critical Statistic

Maternal overdose deaths peak 7-12 months postpartum—not during pregnancy.

Drivers of Postpartum Relapse

Postpartum Overdose Prevention Bundle

Component Action
Naloxone Dispense to patient AND support person before discharge
MOUD Continuity Appointment within 7 days; bridge prescription if needed
Mental Health PHQ-9 screen; treat PPD aggressively
Contraception LARC discussion/placement (prevents rapid repeat pregnancy)
Support Peer recovery specialist contact

Warm Handoffs & Dyadic Care

The Gap

OB care ends at 6 weeks; pediatric care continues but focuses on baby. The mother falls through the cracks.

The Fix: Dyadic Care

Plan of Safe Care (POSC)

Under CAPTA, a Plan of Safe Care is required for infants born with prenatal substance exposure. This is a support plan, not a punishment.